Maxinovel Pty., Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Beverly Hills Australia (2017)

Organization Overview

First Clinical Trial
2018
NCT03412292
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Maxinovel Pty., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

max-40279 (6 trials)

regorafenib (stivarga) (1 trial)

Drugs in Phase 1 Trials (3)

max-10181 (2 trials)

max-40070 (1 trial)

toripalimab (LOQTORZ) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 6